Pyruvate kinase deficiency
Drug research and approvals for pyruvate kinase deficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1 studies of pyruvate kinase deficiency are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 1
- Trials authorized in Canada: 6
- FDA orphan approvals: 1
- EU medicines: 1
Recruiting Now
Newest start dates first, of 1 recruiting on ClinicalTrials.gov ↗- RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)NCT06213402 · Not reported · Hospital Universitari Vall d'Hebron Research Institute · starts Nov 30, 2021
Trials Authorized in Canada
Newest first; search them all in Canada trials| Aug 17, 2023 | A rollover study to provide continued access to mitapivat for participants who previously participated in an agios-sponsored mitapivat studyMITAPIVAT (AG-348) | Agios Pharmaceuticals | Ongoing |
| Mar 9, 2023 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mitapivat in pediatric subjects with pyruvate…MITAPIVAT (AG-348) | Agios Pharmaceuticals | Ongoing |
| Dec 23, 2021 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mitapivat in pediatric subjects with pyruvate…MITAPIVAT (AG-348) | Agios Pharmaceuticals | Ongoing |
| Jan 9, 2019 | An open-label, multicenter, extension study of ag 348 in adult subjects with pyruvate kinase deficiency previously enrolled in ag-348 studiesMITAPIVAT (AG-348) | Agios Pharmaceuticals | Closed |
| May 17, 2018 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ag-348 in not regularly transfused adult subjects with…AG-348 | Agios Pharmaceuticals | Closed |
| Apr 18, 2018 | An open-label study to evaluate the efficacy and safety of ag-348 in regularly transfused adult subjects with pyruvate kinase (pk) deficiencyAG-348 | Agios Pharmaceuticals | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Feb 17, 2022 | PyrukyndTreatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency | Agios Pharmaceuticals, Inc. | Approved |
| Mar 7, 2023 | Autologous CD34+ cells edited with CRISPR/Cas9 and…Treatment of Pyruvate Kinase Deficiency | Consorcio Centro de Investigación Biomédica en Red (CIBER) | Designated |
| Mar 23, 2016 | lentiviral vector containing the human liver and erythroid…Treatment of pyruvate kinase deficiency. | Rocket Pharmaceuticals, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 9, 2022 | Pyrukyndmitapivat · orphan | Agios Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA